{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T08:22:25Z","timestamp":1790497345600,"version":"4.1.0"},"reference-count":95,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T00:00:00Z","timestamp":1744156800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Gemcitabine (GEM), a nucleoside analog chemotherapy agent, has been widely used in the treatment of various cancers. In recent years, there has been growing interest in understanding the immunomodulatory or immunosuppressive effects of GEM. The immunomodulatory roles of GEM could influence the anti-tumor immune responses via several mechanisms, such as modulation of antigen presentation, cytokine production, and immune cell population. Furthermore, there is evidence that GEM enhances the therapeutic efficacy of immunotherapies, including oncolytic viruses, immune checkpoint inhibitors, CAR T-cells, and therapeutic vaccines. On the other hand, accumulating evidence also proposed that GEM may act as an immunosuppressive agent within the tumor microenvironment, resulting in immune evasion of tumor cells and tumor growth. These paradoxical roles of GEM in modifying immune responses highlight the complexity of GEM interaction with immune cells and responses within the tumor microenvironment. This review aims to provide an overview of the immunomodulatory and immunosuppressive effects of GEM within the tumor microenvironment and how GEM affects the efficacy of cancer immunotherapy.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1536428","type":"journal-article","created":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:23:20Z","timestamp":1744161800000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Gemcitabine: immunomodulatory or immunosuppressive role in the tumor microenvironment"],"prefix":"10.3389","volume":"16","author":[{"given":"Mahnaz","family":"Nemati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chou-Yi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Nathiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Ravi","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enwa Felix","family":"Oghenemaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthena","family":"Kariem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parjinder","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak","family":"Bhanot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hjazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tayebeh","family":"Azam Saedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00331.2022","article-title":"Barriers and opportunities for gemcitabine in pancreatic cancer therapy","volume":"324","author":"Beutel","year":"2023","journal-title":"Am J Physiol Physiol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"17588359221086828","DOI":"10.1177\/17588359221086829","article-title":"Safety and effectiveness of gemcitabine for the treatment of classic Kaposi\u2019s sarcoma without visceral involvement","volume":"14","author":"Badalamenti","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/chem.200700260","article-title":"Understanding ribonucleotide reductase inactivation by gemcitabine","volume":"13","author":"Cerqueira","year":"2007","journal-title":"Chem Eur J"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.33696\/haematology.1.016","article-title":"Gemcitabine in the era of cancer immunotherapy","volume":"1","author":"Piadel","year":"2020","journal-title":"J Clin Haematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-1692","article-title":"Targeting the microenvironment to overcome gemcitabine resistance in pancreatic cancer","volume":"80","author":"Carpenter","year":"2020","journal-title":"Cancer Res"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-020-02429-0","article-title":"Effect of Gemcitabine based chemotherapy on the immunogenicity of pancreatic tumour cells and T-cells","volume":"23","author":"Smith","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ejphar.2014.07.041","article-title":"Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer","volume":"741","author":"de Sousa Cavalcante","year":"2014","journal-title":"Eur J Pharmacol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"v7","DOI":"10.1093\/annonc\/mdj941","article-title":"Cellular pharmacology of gemcitabine","volume":"17","author":"Mini","year":"2006","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cancers9110157","article-title":"Pancreatic cancer chemoresistance to gemcitabine","volume":"9","author":"Amrutkar","year":"2017","journal-title":"Cancers (Basel)"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41401-021-00616-5","article-title":"Virus against virus: strategies for using adenovirus vectors in the treatment of HPV-induced cervical cancer","volume":"42","author":"Ghanaat","year":"2021","journal-title":"Acta Pharmacol Sin"},{"key":"B11","doi-asserted-by":"publisher","first-page":"107586","DOI":"10.1016\/j.pharmthera.2020.107586","article-title":"Strategies for enhancing intratumoral spread of oncolytic adenoviruses","volume":"213","author":"Goradel","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1012806","article-title":"Immunovirotherapy: the role of antibodies based therapeutic combination with oncolytic viruses","volume":"13","author":"Jafari","year":"2022","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2021-0802","article-title":"Oncolytic virotherapy as promising immunotherapy against cancer: mechanisms of resistance to oncolytic viruses","volume":"18","author":"Goradel","year":"2021","journal-title":"Futur Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"100639","DOI":"10.1016\/j.currproblcancer.2020.100639","article-title":"Oncolytic virotherapy: Challenges and solutions","volume":"45","author":"Goradel","year":"2021","journal-title":"Curr Probl Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"108611","DOI":"10.1016\/j.pharmthera.2024.108611","article-title":"Nanotechnology and nano-sized tools: Newer approaches to circumvent oncolytic adenovirus limitations","volume":"256","author":"Shirazi","year":"2024","journal-title":"Pharmacol Ther"},{"key":"B16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.biochi.2022.10.008","article-title":"History of how viruses can fight cancer: From the miraculous healings to the approval of oncolytic viruses","volume":"206","author":"Bifulco","year":"2023","journal-title":"Biochimie"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-1088","article-title":"Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV","volume":"15","author":"Angelova","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v132.7","article-title":"Enhanced antitumoral activity of oncolytic herpes simplex virus with gemcitabine using colorectal tumor models","volume":"132","author":"Esaki","year":"2013","journal-title":"Int J Cancer"},{"key":"B19","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3892\/or.2018.6817","article-title":"Gemcitabine combined with an engineered oncolytic vaccinia virus exhibits a synergistic suppressive effect on the tumor growth of pancreatic cancer","volume":"41","author":"Chen","year":"2019","journal-title":"Oncol Rep"},{"key":"B20","doi-asserted-by":"publisher","first-page":"82728","DOI":"10.18632\/oncotarget.21095","article-title":"ING4 expressing oncolytic vaccinia virus promotes anti-tumor efficiency and synergizes with gemcitabine in pancreatic cancer","volume":"8","author":"Wu","year":"2017","journal-title":"Oncotarget"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2019.10901","article-title":"Chemovirotherapy for pancreatic cancer: Gemcitabine plus oncolytic measles vaccine virus","volume":"18","author":"May","year":"2019","journal-title":"Oncol Lett"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v131.1","article-title":"Effects of capsid-modified oncolytic adenoviruses and their combinations with gemcitabine or silica gel on pancreatic cancer","volume":"131","author":"Kangasniemi","year":"2012","journal-title":"Int J Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00229","article-title":"Chemovirotherapy of lung squamous cell carcinoma by combining oncolytic adenovirus with gemcitabine","volume":"10","author":"Liu","year":"2020","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2017.03.009","article-title":"Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer","volume":"396","author":"Jung","year":"2017","journal-title":"Cancer Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2008","article-title":"Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo","volume":"15","author":"Leitner","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1038\/471561a","article-title":"Melanoma drug wins US approval","volume":"471","author":"Ledford","year":"2011","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.21037\/aob-21-3","article-title":"A narrative review of immune checkpoint mechanisms and current immune checkpoint therapy","volume":"7","author":"Peng","year":"2022","journal-title":"Ann Blood"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0343-4","article-title":"Immune checkpoint signaling and cancer immunotherapy","volume":"30","author":"He","year":"2020","journal-title":"Cell Res"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol29050247","article-title":"Immune checkpoint inhibitors in cancer therapy","volume":"29","author":"Shiravand","year":"2022","journal-title":"Curr Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"106694","DOI":"10.1016\/j.intimp.2020.106694","article-title":"Gemcitabine and checkpoint blockade exhibit synergistic anti-tumor effects in a model of murine lung carcinoma","volume":"86","author":"Du","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-016-1037-z","article-title":"Gemcitabine reduces MDSCs, tregs and TGF\u03b2-1 while restoring the teff\/treg ratio in patients with pancreatic cancer","volume":"14","author":"Eriksson","year":"2016","journal-title":"J Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-1231","article-title":"Gemcitabine synergizes with immune checkpoint inhibitors and overcomes resistance in a preclinical model and mesothelioma patients","volume":"24","author":"Tall\u00f3n de Lara","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5990","DOI":"10.3390\/ijms22115990","article-title":"Combined gemcitabine and immune-checkpoint inhibition conquers anti-PD-L1 resistance in low-immunogenic mismatch repair-deficient tumors","volume":"22","author":"Salewski","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2022-0254","article-title":"Low-dose metronomic gemcitabine pretreatments overcome the resistance of breast cancer to immune checkpoint therapy","volume":"15","author":"Zheng","year":"2023","journal-title":"Immunotherapy"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-2959","article-title":"Long-term gemcitabine treatment reshapes the pancreatic tumor microenvironment and sensitizes murine carcinoma to combination immunotherapy","volume":"80","author":"Principe","year":"2020","journal-title":"Cancer Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001367","article-title":"Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis","volume":"8","author":"Ho","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan3682","article-title":"In situ formed reactive oxygen species\u2013responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy","volume":"10","author":"Wang","year":"2018","journal-title":"Sci Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0473","article-title":"Ipilimumab and gemcitabine for advanced pancreatic cancer: a phase Ib study","volume":"25","author":"Kamath","year":"2020","journal-title":"Oncologist"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley","year":"2023","journal-title":"Lancet"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.21203\/rs.2.22587\/v1","article-title":"Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study","volume":"8","author":"Feng","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13287-020-02128-1","article-title":"CAR T cells in solid tumors: challenges and opportunities","volume":"12","author":"Marofi","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccin Immunother"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1188049","article-title":"From bench to bedside: the history and progress of CAR T cell therapy","volume":"14","author":"Mitra","year":"2023","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1140541","article-title":"Combining chemotherapy with CAR-T cell therapy in treating solid tumors","volume":"14","author":"Wang","year":"2023","journal-title":"Front Immunol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-0426","article-title":"A phase I\/IIa trial using CD19-targeted third-generation CAR T cells for lymphoma and leukemia","volume":"24","author":"Enblad","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B46","doi-asserted-by":"publisher","first-page":"106006","DOI":"10.1016\/j.intimp.2019.106006","article-title":"Gemcitabine enhances cytotoxic activity of effector T-lymphocytes against chemo-resistant cholangiocarcinoma cells","volume":"78","author":"Sawasdee","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00346-0","article-title":"Therapeutic cancer vaccines","volume":"21","author":"Saxena","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: then and now","volume":"16","author":"Morse","year":"2021","journal-title":"Target Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.22034\/iji.2019.80274","article-title":"CEA plasmid as therapeutic DNA vaccination against colorectal cancer","volume":"16","author":"Veisi Malekshahi","year":"2019","journal-title":"Iran J Immunol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"108298","DOI":"10.1016\/j.intimp.2021.108298","article-title":"Heterologous administration of HPV16 E7 epitope-loaded nanocomplexes inhibits tumor growth in mouse model","volume":"101","author":"Goradel","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"109887","DOI":"10.1016\/j.intimp.2023.109887","article-title":"Nanovaccines for cancer immunotherapy: Focusing on complex formation between adjuvant and antigen","volume":"117","author":"Goradel","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2023.2287135","article-title":"Comparative efficacy of human papillomavirus vaccines: systematic review and network meta-analysis","volume":"22","author":"Lin","year":"2023","journal-title":"Expert Rev Vaccines"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3390\/vaccines11121862","article-title":"HBV vaccines: advances and development","volume":"11","author":"Mahmood","year":"2023","journal-title":"Vaccines"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.641307","article-title":"Moving on from sipuleucel-T: new dendritic cell vaccine strategies for prostate cancer","volume":"12","author":"Sutherland","year":"2021","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00429.x","article-title":"Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer","volume":"98","author":"Yanagimoto","year":"2007","journal-title":"Cancer Sci"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-013-1510-y","article-title":"Concomitant gemcitabine therapy negatively affects DC vaccine-induced CD8+ T-cell and B-cell responses but improves clinical efficacy in a murine pancreatic carcinoma model","volume":"63","author":"Bauer","year":"2014","journal-title":"Cancer Immunol Immunother"},{"key":"B57","doi-asserted-by":"publisher","first-page":"3010","DOI":"10.1200\/jco.2009.27.15_suppl.3010","article-title":"Persistent immunity and survival after immunization with a HER2\/neu (HER2) vaccine","volume":"27","author":"Salazar","year":"2009","journal-title":"J Clin Oncol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.v129.4","article-title":"Gemcitabine depletes regulatory T-cells in human and mice and enhances triggering of vaccine-specific cytotoxic T-cells","volume":"129","author":"Rettig","year":"2011","journal-title":"Int J Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1949896","DOI":"10.1080\/2162402X.2021.1949896","article-title":"A therapeutic DNA vaccine and gemcitabine act synergistically to eradicate HPV-associated tumors in a preclinical model","volume":"10","author":"Ramos da Silva","year":"2021","journal-title":"Oncoimmunology"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.991311","article-title":"Gemcitabine-mediated depletion of immunosuppressive dendritic cells enhances the efficacy of therapeutic vaccination","volume":"13","author":"Rep\u00e1raz","year":"2022","journal-title":"Front Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01145-x","article-title":"Development of NK cell-based cancer immunotherapies through receptor engineering","volume":"21","author":"Page","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.754541","article-title":"NK cells in the tumor microenvironment as new potential players mediating chemotherapy effects in metastatic melanoma","volume":"11","author":"Garofalo","year":"2021","journal-title":"Front Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00331","article-title":"Low-dose gemcitabine treatment enhances immunogenicity and natural killer cell-driven tumor immunity in lung cancer","volume":"11","author":"Zhang","year":"2020","journal-title":"Front Immunol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0139809","article-title":"Contrasting effects of the cytotoxic anticancer drug gemcitabine and the EGFR tyrosine kinase inhibitor gefitinib on NK cell-mediated cytotoxicity via regulation of NKG2D ligand in non-small-cell lung cancer cells","volume":"10","author":"Okita","year":"2015","journal-title":"PloS One"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.05.004","article-title":"Administration of gemcitabine after pancreatic tumor resection in mice induces an antitumor immune response mediated by natural killer cells","volume":"151","author":"G\u00fcrlevik","year":"2016","journal-title":"Gastroenterology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1275375","article-title":"Targeting myeloid-derived suppressor cells with gemcitabine to enhance efficacy of adoptive cell therapy in bladder cancer","volume":"14","author":"Bazargan","year":"2023","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.biomaterials.2016.04.010","article-title":"Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapy","volume":"96","author":"Sasso","year":"2016","journal-title":"Biomaterials"},{"key":"B69","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.biomaterials.2018.10.022","article-title":"Gemcitabine nanoparticles promote antitumor immunity against melanoma","volume":"189","author":"Zhang","year":"2019","journal-title":"Biomaterials"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2009.03.015","article-title":"Gemcitabine directly inhibits myeloid derived suppressor cells in BALB\/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice","volume":"9","author":"Le","year":"2009","journal-title":"Int Immunopharmacol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.014","article-title":"Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy","volume":"41","author":"Tay","year":"2023","journal-title":"Cancer Cell"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0175-7","article-title":"Regulatory T cells in cancer immunosuppression\u2014implications for anticancer therapy","volume":"16","author":"Togashi","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B73","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","article-title":"Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review","volume":"22","author":"Li","year":"2024","journal-title":"J Transl Med"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1177\/0300060514561504","article-title":"Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer","volume":"43","author":"Chen","year":"2015","journal-title":"J Int Med Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02620-x","article-title":"Alterations in regulatory T cells and immune checkpoint molecules in pancreatic cancer patients receiving FOLFIRINOX or gemcitabine plus nab-paclitaxel","volume":"23","author":"Sams","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1002\/ijc.v133.1","article-title":"Low-dose gemcitabine depletes regulatory T cells and improves survival in the orthotopic Panc02 model of pancreatic cancer","volume":"133","author":"Shevchenko","year":"2013","journal-title":"Int J Cancer"},{"key":"B77","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41577-019-0210-z","article-title":"Dendritic cells in cancer immunology and immunotherapy","volume":"20","author":"Wculek","year":"2020","journal-title":"Nat Rev Immunol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-023-00990-6","article-title":"Dendritic cell subsets in cancer immunity and tumor antigen sensing","volume":"20","author":"Del Prete","year":"2023","journal-title":"Cell Mol Immunol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12943-024-01972-6","article-title":"CTLs heterogeneity and plasticity: implications for cancer immunotherapy","volume":"23","author":"Peng","year":"2024","journal-title":"Mol Cancer"},{"key":"B80","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1093\/jjco\/hyp112","article-title":"Regular dose of gemcitabine induces an increase in CD14+ monocytes and CD11c+ dendritic cells in patients with advanced pancreatic cancer","volume":"39","author":"Soeda","year":"2009","journal-title":"Jpn J Clin Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2013.12.022","article-title":"Gemcitabine-treated pancreatic cancer cell medium induces the specific CTL antitumor activity by stimulating the maturation of dendritic cells","volume":"19","author":"Pei","year":"2014","journal-title":"Int Immunopharmacol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.pan.2015.04.001","article-title":"Gemcitabine sensitizes pancreatic cancer cells to the CTLs antitumor response induced by BCG-stimulated dendritic cells via a Fas-dependent pathway","volume":"15","author":"Pei","year":"2015","journal-title":"Pancreatology"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3211","DOI":"10.3390\/ijms25063211","article-title":"Gemcitabine modulates HLA-I regulation to improve tumor antigen presentation by pancreatic cancer cells","volume":"25","author":"Larson","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"12000","DOI":"10.1038\/s41598-018-30437-2","article-title":"Gemcitabine treatment promotes immunosuppressive microenvironment in pancreatic tumors by supporting the infiltration, growth, and polarization of macrophages","volume":"8","author":"Deshmukh","year":"2018","journal-title":"Sci Rep"},{"key":"B85","doi-asserted-by":"publisher","first-page":"100743","DOI":"10.1016\/j.tranon.2020.01.004","article-title":"Gemcitabine recruits M2-type tumor-associated macrophages into the stroma of pancreatic cancer","volume":"13","author":"Bulle","year":"2020","journal-title":"Transl Oncol"},{"key":"B86","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-822527-1.00010-1","article-title":"Intervention of IL-8-CXCR2 axis to reverse the resistance to GBM therapies","volume-title":"New Targeting in the Reversal of Resistant Glioblastomas","author":"Angara","year":"2021"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063555","article-title":"Macrophage migration and invasion is regulated by MMP10 expression","volume":"8","author":"Murray","year":"2013","journal-title":"PloS One"},{"key":"B88","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.3390\/cancers12071978","article-title":"Depletion of macrophages improves therapeutic response to gemcitabine in murine pancreas cancer","volume":"12","author":"Buchholz","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B89","doi-asserted-by":"publisher","first-page":"116930","DOI":"10.1016\/j.biopha.2024.116930","article-title":"Macrophage polarization in the tumor microenvironment: emerging roles and therapeutic potentials","volume":"177","author":"Zhang","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B90","doi-asserted-by":"publisher","first-page":"6995","DOI":"10.3390\/ijms22136995","article-title":"Macrophage polarization states in the tumor microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.v120.3","article-title":"Macrophage polarity in cancer: A review","volume":"120","author":"Najafi","year":"2019","journal-title":"J Cell Biochem"},{"key":"B92","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-024-00522-z","article-title":"Targeting M2-like tumor-associated macrophages is a potential therapeutic approach to overcome antitumor drug resistance","volume":"8","author":"Wang","year":"2024","journal-title":"NPJ Precis Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1900930","article-title":"Tumor microenvironment following Gemcitabine treatment favors differentiation of immunosuppressive Ly6Chigh myeloid cells","volume":"204","author":"Wu","year":"2020","journal-title":"J Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01399","article-title":"Lipid metabolic pathways confer the immunosuppressive function of myeloid-derived suppressor cells in tumor","volume":"10","author":"Yan","year":"2019","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2019.02.014","article-title":"RS 504393 inhibits M-MDSCs recruiting in immune microenvironment of bladder cancer after gemcitabine treatment","volume":"109","author":"Mu","year":"2019","journal-title":"Mol Immunol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1536428\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,9]],"date-time":"2025-04-09T01:23:23Z","timestamp":1744161803000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1536428\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,9]]},"references-count":95,"alternative-id":["10.3389\/fimmu.2025.1536428"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1536428","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,9]]},"article-number":"1536428"}}